Close Menu

NEW YORK – A new study has identified an apparent role for the PAK4 oncogene in anti-PD-1 checkpoint immunotherapy, prompting a Phase I clinical trial of a PAK4 inhibitor in combination with the PD-1 targeting drug nivolumab (Opdivo from Bristol-Myers Squibb) in around 175 individuals with advanced solid tumors or non-Hodgkin's lymphoma.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.